Valuation: Linc AB

Market Cap 4.09B 423M 371M 344M 316M 598M 40.47B 609M 1.61B 19.88B 1.59B 1.55B 68.64B P/E 2024
3.84x
P/E 2025 -10.1x
Enterprise Value 3.81B 394M 345M 320M 294M 556M 37.67B 567M 1.49B 18.5B 1.48B 1.45B 63.88B EV / Sales 2024
3.45x
EV / Sales 2025 -9.06x
Free-Float
36.64%
Yield 2024 *
-
Yield 2025 -
1 day+0.71%
1 week-1.53%
Current month-0.56%
1 month-0.42%
3 months-4.85%
6 months+10.30%
Current year+1.43%
1 week 69.6
Extreme 69.6
72.3
1 month 66.6
Extreme 66.6
73.7
Current year 58.9
Extreme 58.9
78.1
1 year 58.9
Extreme 58.9
83.6
3 years 52.2
Extreme 52.2
103.4
5 years 43.8
Extreme 43.8
109.9
10 years 43.8
Extreme 43.8
118.2
Manager TitleAgeSince
Chief Executive Officer 52 2019-12-31
Director of Finance/CFO 44 2019-12-31
Director TitleAgeSince
Chairman 73 1990-12-31
Director/Board Member 52 2019-12-31
Director/Board Member 60 2019-12-31
Date Insider Type Main position Quantity % Market Cap.
04-27Buy

Director

20,000 0.0345%
04-27Buy

Director

3,000 0.0052%
04-24Buy

Director

9,000 0.0155%
Change 5-day change 1-year change 3-year change Capi.($)
+0.43%-1.53%-10.51%+16.09% 423M
+1.33%+2.01%+11.76%-2.56% 155M
Average +1.02%-2.77%+0.63%+6.76% 289.13M
Weighted average by Cap. +0.88%-3.44%-4.52%+11.08%

Financials

2024 2025
Net sales 1.29B 133M 117M 108M 99.68M 189M 12.76B 192M 506M 6.27B 501M 490M 21.65B -414M -42.76M -37.5M -34.74M -31.96M -60.45M -4.09B -61.63M -162M -2.01B -161M -157M -6.94B
Net income 1.3B 134M 118M 109M 100M 190M 12.87B 194M 510M 6.32B 505M 494M 21.82B -400M -41.28M -36.2M -33.53M -30.85M -58.36M -3.95B -59.49M -157M -1.94B -155M -152M -6.7B
Net Debt -550M -56.77M -49.79M -46.12M -42.43M -80.26M -5.43B -81.82M -216M -2.67B -213M -209M -9.22B -284M -29.33M -25.73M -23.83M -21.92M -41.47M -2.81B -42.27M -111M -1.38B -110M -108M -4.76B
Logo Linc AB
Linc AB is a Sweden-based investment company. Linc invests in product-oriented companies within the Nordic Life Science industry - primarily in pharmaceutical and medical technology companies. The investments are made in both private and public companies and in research and operational companies. Typically, investments in drug development take place in an earlier phase compared to investments in medical technology. Linc Invest is an active and long-term owner with a wide industrial network to support the portfolio companies. The Company works together with the management, founders and board to realize the inherent potential that exists in the investment, have ambitious plans for further development and expansion and actively participate in the nomination committee work.
Employees
2
Date Price Change Volume
26-07-13 SEK 70.70 +0.43% 10,763
26-07-10 SEK 70.40 -1.54% 18,602
26-07-09 SEK 71.50 +2.14% 34,221
26-07-08 SEK 70.00 -0.43% 19,683
26-07-07 SEK 70.30 -2.09% 21,491
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
70.40SEK
Average target price
71.00SEK
Spread / Average Target
+0.85%
  1. Stock Market
  2. Stocks
  3. LINC Stock